NCT02419378View on ClinicalTrials.gov

Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential

PHASE4CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

July 31, 2020

Study Completion Date

November 30, 2020

Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
DRUG

Alemtuzumab

Trial Locations (1)

48149

Universitätsklinikum Münster, Klinik für Allgemeine Neurologie, Münster

All Listed Sponsors
collaborator

Genzyme, a Sanofi Company

INDUSTRY

lead

University Hospital Muenster

OTHER

NCT02419378 - Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential | Biotech Hunter | Biotech Hunter